ClinicalTrials.gg
Active, not recruitingNCT04908189Updated Sep 11, 2026Results posted

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

A Phase 3 interventional study of Deucravacitinib and Placebo in Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 138 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
729
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 3 of them phase 3. Arthritis, Psoriatic · Bristol-Myers Squibb.

Started
2021
with 1 other
Phase 3
4 of 12
1 open now
Registered
8th of 12
by date

Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, this one is one of 2 that started in 2021, is one of 4 in phase 3, and was the 8th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

1 of the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb is open now. Recruiting first, the newest first:

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Psoriatic arthritis
  • PsA
  • Deucravacitinib
  • BMS-986165
  • Apremilast
  • Otezla
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at Screening
  • Meets the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening
  • Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at Screening
  • Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and Day 1
  • Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening
  • Must have completed the week 52 treatment for the optional open-label long-term extension period

Exclusion criteria

Exclusion Criteria:

  • Nonplaque psoriasis at Screening or Day 1
  • Other condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis
  • History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease)
  • Active fibromyalgia
  • Received an approved or biologic therapy for the treatment of PsA or PsO

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
729 participants (actual)

Study arms

  • Experimental
    Deucravacitinib

    Drug: Deucravacitinib

  • Placebo comparator
    Placebo

    Drug: Deucravacitinib · Other: Placebo

  • Other
    Apremilast

    Drug: Apremilast

Interventions

  • Specified dose on specified days

    Also known as: BMS-986165

  • OtherPlacebo

    Specified dose on specified days

  • Specified dose on specified days

    Also known as: Otezla

06

What researchers measure

Primary outcomes

  1. Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16

    The American College of Rheumatology (ACR) 20 is defined as 20% improvement over baseline in tender (68) and swollen (66) joint counts and a 20% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

    Time frame: Week 16

Secondary outcomes

  1. Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16

    DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.

    Time frame: Baseline, Week 16

  2. Change From Baseline in Health Assessment Quiestionnaire - Disability Index (HAQ-DI) at Week 16

    HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.

    Time frame: Baseline, Week 16

  3. Number of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75) at Week 16

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

    Time frame: Week 16

  4. Change From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) Score at Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.

    Time frame: Baseline, Week 16

  5. Number of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16

    Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

    Time frame: Week 16

  6. Number of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16

    Number participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count ≤ 1 2. Swollen joint count ≤ 1 3. Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain ≤ 15 5. Patient Global Assessment of PsA disease activity ≤ 20 6. HAQ-DI ≤ 0.5 7. Tender enthesial points ≤ 1

    Time frame: Week 16

  7. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16

    FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.

    Time frame: Baseline, Week 16

  8. Number of Participants Meeting Dactylitis Resolution at Week 16

    Number of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count ≥ 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.

    Time frame: Week 16

  9. Number of Participants Meeting American College of Rheumatology (ACR) 50 at Week 16

    The American College of Rheumatology (ACR) 50 is defined as 50% improvement over baseline in tender (68) and swollen (66) joint counts and a 50% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

    Time frame: Week 16

  10. Number of Participants Meeting American College of Rheumatology (ACR) 70 at Week 16

    The American College of Rheumatology (ACR) 70 is defined as 70% improvement over baseline in tender (68) and swollen (66) joint counts and a 70% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

    Time frame: Week 16

  11. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI)

    HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16

  12. Number of Participants Who Achieve a Clinically Meaningful Improvement in HAQ-DI Score at Week 16

    Number of participants who achieve a clinically meaningful improvement (≥ 0.35 improvement from baseline) in HAQ-DI score among participants with a HAQ-DI score ≥ 0.35 at baseline. HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered.

    Time frame: Week 16

  13. Number of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75)

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

    Time frame: Weeks 4, 8, 12, 16

  14. Number of Participants Meeting Psoriasis Area and Severity Index 90 (PASI 90)

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

    Time frame: Weeks 4, 8, 12, 16

  15. Number of Participants Meeting Psoriasis Area and Severity Index 100 (PASI 100)

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

    Time frame: Weeks 4, 8, 12, 16

  16. Change From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) Score

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.

    Time frame: Baseline, Weeks 4, 12, 16

  17. Number of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI)

    Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

    Time frame: Weeks 4, 8, 12, 16

  18. Number of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC)

    Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \[R\]/left \[L\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.

    Time frame: Weeks 4, 8, 12, 16

  19. Number of Participants Meeting Achievement of Minimal Disease Activity (MDA)

    Number participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count ≤ 1 2. Swollen joint count ≤ 1 3. Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain ≤ 15 5. Patient Global Assessment of PsA disease activity ≤ 20 6. HAQ-DI ≤ 0.5 7. Tender enthesial points ≤ 1

    Time frame: Weeks 4, 8, 12, 16

  20. Change From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.

    Time frame: Baseline, Weeks 4, 12, 16

  21. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score

    FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16

  22. Number of Participants Meeting Dactylitis Resolution

    Number of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count ≥ 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.

    Time frame: Weeks 4, 8, 12, 16

  23. Change From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score

    The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16

  24. Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score

    The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16

  25. Number of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response

    The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.

    Time frame: Weeks 2, 4, 8, 12, 16

  26. Number of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission

    The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.

    Time frame: Weeks 2, 4, 8, 12, 16

  27. Number of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1

    The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.

    Time frame: Weeks 4, 8, 12, 16

  28. Change From Baseline in Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Score

    The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16

  29. Number of Participants With Achievement of Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Low Disease Activity Response

    The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity.

    Time frame: Weeks 2, 4, 8, 12, 16

  30. Number of Participants With Achievement of Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Disease Remission

    The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity.

    Time frame: Weeks 2, 4, 8, 12, 16

  31. Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS)

    The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Weeks 4, 12, 16

  32. Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI)

    Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Weeks 4, 8, 12, 16

  33. Number of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC)

    The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity

    Time frame: Weeks 2, 4, 8, 12, 16

  34. Number of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score

    BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5

    Time frame: Weeks 2, 4, 8, 12, 16

  35. Change From Baseline in The Work Productivity and Activity Impairment (WPAI) at Week 16

    The WPAI is a 6-item questionnaire that includes 2 visual analog scales: 1 for impact of disease on work and 1 for impact of disease on other daily activities. The WPAI also assesses absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 16

  36. Change From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents

    The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Weeks 4, 16

  37. Change From Baseline in Patient-Reported Outcome Measures Information System (PROMIS)

    The Patient-Reported Outcome Measures Information System Sleep Disturbance Short Form 8b assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Weeks 4, 12, 16

07

Results

Posted Apr 13, 2025

Participant flow

Pre-treatment
Participant flow — Pre-treatment
MilestoneDeucravacitinibPlaceboApremilast
Started312312105
Completed312311105
Not completed010
Placebo-Controlled (Week 0 - Week 16)
Participant flow — Placebo-Controlled (Week 0 - Week 16)
MilestoneDeucravacitinibPlaceboApremilast
Started312311105
Completed29229290
Not completed201915
Withdrew: Lack of efficacy130
Withdrew: Adverse event6410
Withdrew: Participant request to discontinue study treatment242
Withdrew: Withdrawal by subject683
Withdrew: Administrative reason by sponsor300
Withdrew: Other reasons200
Active Treatment (Week 16 - Week 52)
Participant flow — Active Treatment (Week 16 - Week 52)
MilestoneDeucravacitinibPlaceboApremilast
Started29229290
Participants switched to deucravacitinib02920
Completed26626979
Not completed262311
Withdrew: Lack of efficacy661
Withdrew: Adverse event973
Withdrew: Participant request to discontinue study treatment334
Withdrew: Withdrawal by subject552
Withdrew: Lost to follow-up210
Withdrew: Other reasons111

Outcome measures

PrimaryNumber of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16

The American College of Rheumatology (ACR) 20 is defined as 20% improvement over baseline in tender (68) and swollen (66) joint counts and a 20% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16
ParticipantsDeucravacitinibPlacebo
Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16169123
SecondaryChange From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16

DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16
score on a scaleDeucravacitinibPlacebo
Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16-1.3133 ± 1.17420-0.9095 ± 1.10470
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.4743 · 95% CI -0.6455 to -0.3031The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryChange From Baseline in Health Assessment Quiestionnaire - Disability Index (HAQ-DI) at Week 16

HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Health Assessment Quiestionnaire - Disability Index (HAQ-DI) at Week 16
score on a scaleDeucravacitinibPlacebo
Change From Baseline in Health Assessment Quiestionnaire - Disability Index (HAQ-DI) at Week 16-0.3103 ± 0.46159-0.2219 ± 0.46858
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0013 · Adjusted mean difference: -0.1126 · 95% CI -0.1814 to -0.0438The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryNumber of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75) at Week 16

PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75) at Week 16
ParticipantsDeucravacitinibPlacebo
Number of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75) at Week 166323
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) Score at Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.

Time frame:
Baseline, Week 16
Reported as:
Mean · Score on a scale
Change From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) Score at Week 16
Score on a scaleDeucravacitinibPlacebo
Change From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) Score at Week 166.194 ± 7.46404.262 ± 7.0328
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0002 · Adjusted mean difference: 2.042 · 95% CI 0.980 to 3.105The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryNumber of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16

Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16
ParticipantsDeucravacitinibPlacebo
Number of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 167466
SecondaryNumber of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16

Number participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count ≤ 1 2. Swollen joint count ≤ 1 3. Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain ≤ 15 5. Patient Global Assessment of PsA disease activity ≤ 20 6. HAQ-DI ≤ 0.5 7. Tender enthesial points ≤ 1

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16
ParticipantsDeucravacitinibPlacebo
Number of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 168046
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16

FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.

Time frame:
Baseline, Week 16
Reported as:
Mean · Score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16
Score on a scaleDeucravacitinibPlacebo
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 162.6 ± 8.171.9 ± 8.54
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.2017 · Adjusted mean difference: 0.8 · 95% CI -0.4 to 2.0The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryNumber of Participants Meeting Dactylitis Resolution at Week 16

Number of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count ≥ 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Dactylitis Resolution at Week 16
ParticipantsDeucravacitinibPlacebo
Number of Participants Meeting Dactylitis Resolution at Week 164336
SecondaryNumber of Participants Meeting American College of Rheumatology (ACR) 50 at Week 16

The American College of Rheumatology (ACR) 50 is defined as 50% improvement over baseline in tender (68) and swollen (66) joint counts and a 50% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Meeting American College of Rheumatology (ACR) 50 at Week 16
ParticipantsDeucravacitinibPlacebo
Number of Participants Meeting American College of Rheumatology (ACR) 50 at Week 169051
SecondaryNumber of Participants Meeting American College of Rheumatology (ACR) 70 at Week 16

The American College of Rheumatology (ACR) 70 is defined as 70% improvement over baseline in tender (68) and swollen (66) joint counts and a 70% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Meeting American College of Rheumatology (ACR) 70 at Week 16
ParticipantsDeucravacitinibPlacebo
Number of Participants Meeting American College of Rheumatology (ACR) 70 at Week 163317
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI)

HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16
Reported as:
Mean · score on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI)
score on a scaleDeucravacitinibPlacebo
Week 2-0.0546 ± 0.38637-0.1335 ± 0.34583
Week 4-0.1547 ± 0.41308-0.1760 ± 0.40042
Week 8-0.2301 ± 0.44365-0.1964 ± 0.43603
Week 12-0.2544 ± 0.45565-0.2236 ± 0.46098
Week 16-0.3103 ± 0.46159-0.2219 ± 0.46858
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0231 · Adjusted mean difference: 0.0643 · 95% CI 0.0088 to 0.1198The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.7865 · Adjusted mean difference: 0.0085 · 95% CI -0.0528 to 0.0697The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.1280 · Adjusted mean difference: -0.0515 · 95% CI -0.1179 to 0.0148The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.1180 · Adjusted mean differnce: -0.0541 · 95% CI -0.1219 to 0.0137The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0013 · Adjusted mean difference: -0.1126 · 95% CI -0.1814 to -0.0438The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryNumber of Participants Who Achieve a Clinically Meaningful Improvement in HAQ-DI Score at Week 16

Number of participants who achieve a clinically meaningful improvement (≥ 0.35 improvement from baseline) in HAQ-DI score among participants with a HAQ-DI score ≥ 0.35 at baseline. HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieve a Clinically Meaningful Improvement in HAQ-DI Score at Week 16
ParticipantsDeucravacitinibPlacebo
Number of Participants Who Achieve a Clinically Meaningful Improvement in HAQ-DI Score at Week 16131118
SecondaryNumber of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75)

PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

Time frame:
Weeks 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75)
ParticipantsDeucravacitinibPlacebo
Week 41410
Week 82619
Week 124522
Week 166323
SecondaryNumber of Participants Meeting Psoriasis Area and Severity Index 90 (PASI 90)

PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

Time frame:
Weeks 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Psoriasis Area and Severity Index 90 (PASI 90)
ParticipantsDeucravacitinibPlacebo
Week 443
Week 8107
Week 123115
Week 164113
SecondaryNumber of Participants Meeting Psoriasis Area and Severity Index 100 (PASI 100)

PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.

Time frame:
Weeks 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Psoriasis Area and Severity Index 100 (PASI 100)
ParticipantsDeucravacitinibPlacebo
Week 420
Week 863
Week 12179
Week 16248
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) Score

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.

Time frame:
Baseline, Weeks 4, 12, 16
Reported as:
Mean · Score on a scale
Change From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) Score
Score on a scaleDeucravacitinibPlacebo
Week 43.364 ± 5.84392.771 ± 5.8897
Week 125.419 ± 7.10663.578 ± 6.7537
Week 166.194 ± 7.46404.262 ± 7.0328
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.1147 · Adjusted mean difference: 0.692 · 95% CI -0.168 to 1.551The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0001 · Adjusted mean difference: 1.999 · 95% CI 0.991 to 3.008The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0002 · Adjusted mean difference: 2.042 · 95% CI 0.980 to 3.105The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryNumber of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI)

Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

Time frame:
Weeks 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI)
ParticipantsDeucravacitinibPlacebo
Week 44555
Week 87054
Week 127458
Week 167466
SecondaryNumber of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC)

Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \[R\]/left \[L\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.

Time frame:
Weeks 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC)
ParticipantsDeucravacitinibPlacebo
Week 45355
Week 87355
Week 127566
Week 168675
SecondaryNumber of Participants Meeting Achievement of Minimal Disease Activity (MDA)

Number participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count ≤ 1 2. Swollen joint count ≤ 1 3. Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain ≤ 15 5. Patient Global Assessment of PsA disease activity ≤ 20 6. HAQ-DI ≤ 0.5 7. Tender enthesial points ≤ 1

Time frame:
Weeks 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Achievement of Minimal Disease Activity (MDA)
ParticipantsDeucravacitinibPlacebo
Week 41916
Week 83528
Week 125624
Week 168046
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.

Time frame:
Baseline, Weeks 4, 12, 16
Reported as:
Mean · Score on a scale
Change From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score
Score on a scaleDeucravacitinibPlacebo
Week 40.195 ± 7.70260.300 ± 7.7067
Week 121.245 ± 8.64420.123 ± 9.1804
Week 161.009 ± 9.7740-0.438 ± 9.3388
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.6159 · Adjusted mean difference: -0.284 · 95% CI -1.396 to 0.827The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.1847 · Adjusted mean difference: 0.829 · 95% CI -0.396 to 2.054The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0888 · Adjusted mean difference: 1.145 · 95% CI -0.174 to 2.464The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score

FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16
Reported as:
Mean · Score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score
Score on a scaleDeucravacitinibPlacebo
Week 20.8 ± 6.601.5 ± 6.52
Week 41.3 ± 6.701.6 ± 6.95
Week 82.9 ± 7.531.9 ± 8.54
Week 122.2 ± 8.402.0 ± 8.91
Week 162.6 ± 8.171.9 ± 8.54
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.1924 · Adjusted mean difference: -0.6 · 95% CI -1.6 to 0.3The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.7601 · Adjusted mean difference: -0.2 · 95% CI -1.20 to 0.8The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0303 · Adjusted mean difference: 1.3 · 95% CI 0.1 to 2.4The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.4747 · Adjusted mean difference: 0.5 · 95% CI -0.8 to 1.7The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.2017 · Adjusted mean difference: 0.8 · 95% CI -0.4 to 2.0The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryNumber of Participants Meeting Dactylitis Resolution

Number of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count ≥ 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.

Time frame:
Weeks 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Dactylitis Resolution
ParticipantsDeucravacitinibPlacebo
Week 42430
Week 83127
Week 123929
Week 164336
SecondaryChange From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score

The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16
Reported as:
Mean · Score on a scale
Change From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score
Score on a scaleDeucravacitinibPlacebo
Week 2-0.658 ± 1.3895-0.590 ± 1.2369
Week 4-0.986 ± 1.5902-0.761 ± 1.5206
Week 8-1.419 ± 1.7445-0.849 ± 1.8018
Week 12-1.511 ± 1.9314-0.937 ± 1.9126
Week 16-1.729 ± 2.0150-0.968 ± 1.9075
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.4459 · Adjusted mean difference: -0.077 · 95% CI -0.276 to 0.122The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0461 · Adjusted mean difference: -0.232 · 95% CI -0.460 to -0.004The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.598 · 95% CI -0.857 to -0.339The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.605 · 95% CI -0.882 to -0.327The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.786 · 95% CI -1.071 to -0.501The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryChange From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score

The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16
Reported as:
Mean · Score on a scale
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score
Score on a scaleDeucravacitinibPlacebo
Week 2-4.9619 ± 12.27319-5.9569 ± 12.24097
Week 4-9.0129 ± 11.93271-8.2813 ± 12.79788
Week 8-13.5855 ± 14.33402-10.7292 ± 16.10715
Week 12-15.7385 ± 16.02197-11.8980 ± 16.33187
Week 16-17.5225 ± 16.66002-12.1547 ± 17.74566
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.7025 · Adjusted mean difference: 0.3525 · 95% CI -1.4560 to 2.1609The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.1413 · Adjusted mean difference: -1.3730 · 95% CI -3.2023 to 0.4562The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0007 · Adjused mean difference: -3.7522 · 95% CI -5.9155 to -1.5890The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANOVA · p = <0.0001 · Adjusted mean difference: -4.8072 · 95% CI -7.0388 to -2.5757The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -6.2006 · 95% CI -8.6082 to -3.7930The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryNumber of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response

The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.

Time frame:
Weeks 2, 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response
ParticipantsDeucravacitinibPlacebo
Week 22518
Week 44442
Week 86955
Week 129566
Week 1610478
SecondaryNumber of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission

The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.

Time frame:
Weeks 2, 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission
ParticipantsDeucravacitinibPlacebo
Week 211
Week 421
Week 8124
Week 12208
Week 16309
SecondaryNumber of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1

The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.

Time frame:
Weeks 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1
ParticipantsDeucravacitinibPlacebo
Week 41010
Week 81313
Week 121611
Week 161715
SecondaryChange From Baseline in Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Score

The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16
Reported as:
Mean · Score on a scale
Change From Baseline in Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Score
Score on a scaleDeucravacitinibPlacebo
Week 2-0.3226 ± 0.74392-0.4044 ± 0.70334
Week 4-0.6292 ± 0.84069-0.5888 ± 0.75652
Week 8-0.9992 ± 1.01750-0.7579 ± 0.99991
Week 12-1.1279 ± 1.14379-0.8826 ± 1.03604
Week 16-1.3133 ± 1.17420-0.9095 ± 1.10470
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.5707 · Adjusted mean difference: 0.0318 · 95% CI -0.0782 to 0.1419The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.1862 · Adjusted mean difference: -0.0833 · 95% CI -0.2069 to 0.0402The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0002 · Adjusted mean difference: -0.2958 · 95% CI -0.4497 to -0.1418The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.3262 · 95% CI -0.4889 to -0.1635The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.4743 · 95% CI -0.6455 to -0.3031The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryNumber of Participants With Achievement of Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Low Disease Activity Response

The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity.

Time frame:
Weeks 2, 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants With Achievement of Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Low Disease Activity Response
ParticipantsDeucravacitinibPlacebo
Week 22319
Week 43931
Week 83532
Week 125439
Week 165643
SecondaryNumber of Participants With Achievement of Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Disease Remission

The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity.

Time frame:
Weeks 2, 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants With Achievement of Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Disease Remission
ParticipantsDeucravacitinibPlacebo
Week 2137
Week 42714
Week 85731
Week 126435
Week 168444
SecondaryChange From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS)

The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Weeks 4, 12, 16
Reported as:
Mean · Score on a scale
Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS)
Score on a scaleDeucravacitinibPlacebo
Week 4-0.8037 ± 0.90993-0.7690 ± 0.90884
Week 12-1.5273 ± 1.27441-1.0137 ± 1.17400
Week 16-1.7047 ± 1.32902-1.1434 ± 1.26434
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.2836 · Adjusted mean difference: -0.0758 · 95% CI -0.2144 to 0.0627The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.5548 · 95% CI -0.7396 to -0.3699The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.5835 · 95% CI -0.7826 to -0.3843The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryChange From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI)

Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Weeks 4, 8, 12, 16
Reported as:
Mean · Score on a scale
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI)
Score on a scaleDeucravacitinibPlacebo
Week 4-0.8 ± 1.57-0.7 ± 1.76
Week 8-1.3 ± 1.71-0.9 ± 1.86
Week 12-1.6 ± 1.80-1.0 ± 1.87
Week 16-1.8 ± 1.97-1.2 ± 2.02
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.2143 · Adjusted mean difference: -0.2 · 95% CI -0.4 to 0.1The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0001 · Adjusted mean difference: -0.5 · 95% CI -0.8 to -0.2The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.7 · 95% CI -1.0 to -0.4The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.6 · 95% CI -0.9 to -0.4The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryNumber of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC)

The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity

Time frame:
Weeks 2, 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC)
ParticipantsDeucravacitinibPlacebo
Week 27169
Week 412898
Week 8163126
Week 12176122
Week 16187138
SecondaryNumber of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score

BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5

Time frame:
Weeks 2, 4, 8, 12, 16
Reported as:
Count of participants · Participants
Number of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score
ParticipantsDeucravacitinibPlacebo
Week 221
Week 461
Week 8125
Week 12114
Week 16174
SecondaryChange From Baseline in The Work Productivity and Activity Impairment (WPAI) at Week 16

The WPAI is a 6-item questionnaire that includes 2 visual analog scales: 1 for impact of disease on work and 1 for impact of disease on other daily activities. The WPAI also assesses absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 16
Reported as:
Mean · Score on a scale
Change From Baseline in The Work Productivity and Activity Impairment (WPAI) at Week 16
Score on a scaleDeucravacitinibPlacebo
Absenteeism-0.59 ± 21.4061.56 ± 22.108
Presenteeism-13.97 ± 23.380-5.96 ± 22.238
Work Productivity-13.71 ± 24.087-5.79 ± 23.951
Activity Impairment-15.72 ± 25.226-8.16 ± 24.178
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.8316 · Adjusted mean difference: -0.38 · 95% CI -3.91 to 3.15The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.1060 · Adjusted mean difference: -2.95 · 95% CI -6.54 to 0.63The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.1578 · Adjusted mean difference: -2.71 · 95% CI -6.47 to 1.05The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -7.59 · 95% CI -10.96 to -4.22The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryChange From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents

The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Weeks 4, 16
Reported as:
Mean · Score on a scale
Change From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents
Score on a scaleDeucravacitinibPlacebo
Week 4 Utility Score0.0505 ± 0.176580.0655 ± 0.19080
Week 16 Utility Score0.0990 ± 0.211130.0770 ± 0.22126
Week 4 Mobility-0.2 ± 0.74-0.2 ± 0.76
Week 16 Mobility-0.3 ± 0.92-0.3 ± 0.87
Week 4 Self-Care-0.1 ± 0.73-0.2 ± 0.71
Week 16 Self-Care-0.2 ± 0.83-0.2 ± 0.81
Week 4 Usual Activities-0.1 ± 0.76-0.2 ± 0.73
Week 16 Usual Activities-0.3 ± 0.84-0.3 ± 0.83
Week 4 Pain/Discomfort-0.3 ± 0.75-0.3 ± 0.80
Week 16 Pain/Discomfort-0.5 ± 0.89-0.4 ± 0.93
Week 4 Anxiety/Depression-0.1 ± 0.76-0.1 ± 0.78
Week 16 Anxiety/Depression-0.1 ± 0.770.0 ± 0.88
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.8487 · Adjusted mean difference: -0.0026 · 95% CI -0.0291 to 0.0239The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0171 · Adjusted mean difference: 0.0365 · 95% CI 0.0065 to 0.0665The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.9254 · Adjusted mean difference: 0.0 · 95% CI -0.1 to 0.1The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0566 · Adjusted mean difference: -0.1 · 95% CI -0.2 to 0.0The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.8933 · Ajudted mean difference: 0.0 · 95% CI -0.1 to 0.1The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0738 · Adjusted mean difference: -0.1 · 95% CI -0.2 to 0.0The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.6176 · Adjusted mean difference: 0.0 · 95% CI -0.1 to 0.1The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.1544 · Adjusted mean difference: -0.1 · 95% CI -0.2 to 0.0The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.4707 · Adjusted mean difference: 0.0 · 95% CI -0.2 to 0.1The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.0114 · Adjusted mean difference: -0.2 · 95% CI -0.3 to 0.0The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.6594 · Adjusted mean difference: 0.0 · 95% CI -0.1 to 0.1The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.7123 · Adjusted mean difference: 0.0 · 95% CI -0.1 to 0.1The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
SecondaryChange From Baseline in Patient-Reported Outcome Measures Information System (PROMIS)

The Patient-Reported Outcome Measures Information System Sleep Disturbance Short Form 8b assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Weeks 4, 12, 16
Reported as:
Mean · Score on a scale
Change From Baseline in Patient-Reported Outcome Measures Information System (PROMIS)
Score on a scaleDeucravacitinibPlacebo
Week 4-1.35 ± 6.958-1.41 ± 6.156
Week 12-1.76 ± 7.945-1.48 ± 7.145
Week 16-2.21 ± 7.447-1.53 ± 7.134
Statistical analysis
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.9834 · Adjusted mean difference: -0.01 · 95% CI -0.99 to 0.97The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.6099 · Adjusted mean difference: -0.29 · 95% CI -1.39 to 0.82The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo
  • Deucravacitinib vs Placebo · ANCOVA · p = 0.2205 · Adjusted mean difference: -0.66 · 95% CI -1.71 to 0.40The adjusted mean difference and p-value are based on the total randomized population, which is 312 for Deucravacitinib and 312 for Placebo

Adverse events

Collected over All-cause mortality was assessed for all participants from date of randomization to their study completion (up to approximately 30 months). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 30 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Deucravacitinib-Controlled0/312 (0%)6/312 (1.9%)89/312 (28.5%)
Placebo-Controlled1/312 (0.3%)3/311 (1%)93/311 (29.9%)
Apremilast-Controlled0/105 (0%)4/105 (3.8%)39/105 (37.1%)
Deucravacitinib-Active Treatment0/292 (0%)12/292 (4.1%)90/292 (30.8%)
Placebo-Active Treatment1/292 (0.3%)13/292 (4.5%)106/292 (36.3%)
Apremilast-Active Treatment0/90 (0%)6/90 (6.7%)32/90 (35.6%)
Deucravacitinib-Open Label Extension0/245 (0%)16/245 (6.5%)58/245 (23.7%)
Placebo-Open Label Extension1/254 (0.4%)13/254 (5.1%)61/254 (24%)
Apremilast-Open Label Extension0/70 (0%)6/70 (8.6%)23/70 (32.9%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventDeucravacitinib-ControlledPlacebo-ControlledApremilast-ControlledDeucravacitinib-Active TreatmentPlacebo-Active TreatmentApremilast-Active TreatmentDeucravacitinib-Open Label ExtensionPlacebo-Open Label ExtensionApremilast-Open Label Extension
Atrioventricular block second degreeCardiac disorders0/3120/3110/1050/2920/2920/900/2450/2541/70
Rhegmatogenous retinal detachmentEye disorders0/3120/3110/1050/2920/2920/900/2450/2541/70
PneumoniaInfections and infestations2/3120/3110/1050/2922/2920/900/2451/2541/70
Vestibular neuronitisInfections and infestations0/3120/3110/1050/2920/2920/900/2450/2541/70
Limb injuryInjury, poisoning and procedural complications1/3120/3110/1050/2920/2920/900/2450/2541/70
OsteoarthritisMusculoskeletal and connective tissue disorders0/3120/3110/1050/2921/2921/901/2450/2541/70
Acute myocardial infarctionCardiac disorders0/3120/3110/1050/2921/2921/901/2450/2540/70
Inguinal herniaGastrointestinal disorders0/3120/3110/1050/2920/2921/900/2450/2540/70
Urinary tract infectionInfections and infestations0/3120/3110/1050/2920/2921/900/2450/2540/70
SpondylolisthesisMusculoskeletal and connective tissue disorders0/3120/3110/1050/2920/2921/900/2450/2540/70
Most frequent other events
Most frequent other events
EventDeucravacitinib-ControlledPlacebo-ControlledApremilast-ControlledDeucravacitinib-Active TreatmentPlacebo-Active TreatmentApremilast-Active TreatmentDeucravacitinib-Open Label ExtensionPlacebo-Open Label ExtensionApremilast-Open Label Extension
Upper respiratory tract infectionInfections and infestations19/31213/3114/10527/29228/2928/9027/24516/25413/70
NasopharyngitisInfections and infestations14/31221/3114/10527/29236/2924/9014/24513/2545/70
DiarrhoeaGastrointestinal disorders11/31215/31111/10510/2926/29211/902/2455/2543/70
COVID-19Infections and infestations22/31217/3117/10519/29230/2928/9013/24521/2540/70
HeadacheNervous system disorders13/31211/3118/1054/2924/2925/902/2453/2540/70
NauseaGastrointestinal disorders7/3126/3117/1055/2928/2922/903/2452/2540/70
HypertensionVascular disorders8/3128/3117/1057/2928/2920/902/2457/2542/70
Urinary tract infectionInfections and infestations3/3123/3112/1058/2925/2925/901/2452/2542/70
Psoriatic arthropathyMusculoskeletal and connective tissue disorders5/31210/3112/1055/29213/2925/908/2456/2542/70

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DeucravacitinibPlaceboApremilastTotal
Mean48.7 ± 11.7349.3 ± 12.1849.1 ± 13.4749.0 ± 12.17
Sex: Female, Male
Sex: Female, Male(Participants)DeucravacitinibPlaceboApremilastTotal
Female15316856377
Male15914449352
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DeucravacitinibPlaceboApremilastTotal
Hispanic or Latino545016120
Not Hispanic or Latino19520064459
Unknown or Not Reported636225150
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DeucravacitinibPlaceboApremilastTotal
American Indian or Alaska Native137424
Asian544528127
Native Hawaiian or Other Pacific Islander0101
Black or African American0000
White22324065528
More than one race0000
Unknown or Not Reported2219849
08

Study locations

138 sites
  • Local Institution - 0149
    Mountain Brook, Alabama 35223, United States
  • Local Institution - 0212
    Sacramento, California 95815, United States
  • Local Institution - 0188
    Whittier, California 90602, United States
  • Local Institution - 0192
    Skokie, Illinois 60076, United States
  • Local Institution - 0203
    Hopkinsville, Kentucky 42240, United States
  • Local Institution - 0195
    Baton Rouge, Louisiana 70836, United States
  • Local Institution - 0169
    Cumberland, Maryland 21502, United States
  • Local Institution - 0034
    Okemos, Michigan 48864, United States
  • Local Institution - 0133
    Eagan, Minnesota 55121, United States
  • Local Institution - 0109
    Hattiesburg, Mississippi 39402, United States
  • Local Institution - 0108
    New York, New York 10003, United States
  • Local Institution - 0186
    Rochester, New York 14642, United States
  • Local Institution - 0196
    Charlotte, North Carolina 28277, United States
  • Local Institution - 0180
    Cleveland, Ohio 44106, United States
  • Local Institution - 0189
    Oklahoma City, Oklahoma 73116, United States
  • Local Institution - 0147
    Portland, Oregon 97239, United States
  • Local Institution - 0016
    Duncansville, Pennsylvania 16635, United States
  • Local Institution - 0182
    Summerville, South Carolina 29486, United States
  • Local Institution - 0167
    Lubbock, Texas 79424, United States
  • Local Institution - 0070
    Mesquite, Texas 75150, United States
  • Local Institution - 0184
    Plano, Texas 75024, United States
  • Local Institution - 0187
    Seattle, Washington 98122, United States
  • Local Institution - 0190
    Franklin, Wisconsin 53132, United States
  • Local Institution - 0175
    Milwaukee, Wisconsin 53217, United States
  • Local Institution - 0048
    La Plata, Buenos Aires 1900, Argentina
  • Local Institution - 0038
    San Isidro, Buenos Aires 1642, Argentina
  • Local Institution - 0039
    CABA, Distrito Federal C1015, Argentina
  • Local Institution - 0171
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Local Institution - 0200
    Buenos Aires, 1426, Argentina
  • Local Institution - 0003
    Botany, New South Wales 2019, Australia
  • Local Institution - 0018
    Parramatta, New South Wales 2150, Australia
  • Local Institution - 0004
    Maroochydore, Queensland 4558, Australia
  • Local Institution - 0099
    Woodville, South Australia 5011, Australia
  • Local Institution - 0002
    Camberwell, Victoria 3124, Australia
  • Local Institution - 0017
    Geelong, Victoria 3220, Australia
  • Local Institution - 0078
    Brussels, 1200, Belgium
  • Local Institution - 0058
    Ghent, 9000, Belgium
  • Local Institution - 0061
    Liège, 4000, Belgium
  • Local Institution - 0111
    Vancouver, British Columbia V5Z 4E8, Canada
  • Local Institution - 0006
    Hamilton, Ontario L8N 1Y2, Canada
  • Local Institution - 0030
    Markham, Ontario L3P 1X3, Canada
  • Local Institution - 0036
    Toronto, Ontario M5T 2S6, Canada
  • Local Institution - 0001
    Québec, G1V 3M7, Canada
  • Local Institution - 0126
    Bengbu, Anhui 233004, China
  • Local Institution - 0152
    Beijing, Beijing Municipality 100083, China
  • Local Institution - 0146
    Beijing, Beijing Municipality 100730, China
  • Local Institution - 0153
    Guangzhou, Guangdong 510180, China
  • Local Institution - 0135
    Guangzhou, Guangdong 510317, China
  • Local Institution - 0206
    Shenzhen, Guangdong 518020, China
  • Local Institution - 0127
    Zhengzhou, Henan 450000, China
  • Local Institution - 0170
    Changsha, Hunan 410008, China
  • Local Institution - 0161
    Changsha, Hunan 410011, China
  • Local Institution - 0125
    Changzhou, Jiangsu 213003, China
  • Local Institution - 0138
    Nanjing, Jiangsu 210029, China
  • Local Institution - 0139
    Nantong, Jiangsu 226001, China
  • Local Institution - 0163
    Wuxi, Jiangsu 214023, China
  • Local Institution - 0148
    Jiujiang, Jiangxi 332000, China
  • Local Institution - 0131
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0156
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0140
    Pingxiang, Jiangxi 337055, China
  • Local Institution - 0158
    Baotou, Neimeng 014010, China
  • Local Institution - 0157
    Hohhot, Neimeng 010050, China
  • Local Institution - 0154
    Xi'an, Shan3xi 710004, China
  • Local Institution - 0207
    Shanghai, Shanghai Municipality 200052, China
  • Local Institution - 0164
    Chengdu, Sichuan 610072, China
  • Local Institution - 0117
    Ürümqi, Xinjiang 830001, China
  • Local Institution - 0134
    Kunming, Yunnan 650032, China
  • Local Institution - 0129
    Wenzhou, Zhejiang 32500, China
  • Local Institution - 0072
    Barranquilla, Atlántico 080002, Colombia
  • Local Institution - 0015
    Bogotá, 110221, Colombia
  • Local Institution - 0020
    Cali, 760035, Colombia
  • Local Institution - 0022
    Chía, 250001, Colombia
  • Local Institution - 0019
    Medellín, 50036, Colombia
  • Local Institution - 0010
    Brno, 638 00, Czechia
  • Local Institution - 0009
    Ostrava, 702 00, Czechia
  • Local Institution - 0035
    Ostrava, 702 00, Czechia
  • Local Institution - 0011
    Prague, 12850, Czechia
  • Local Institution - 0023
    Uherské Hradiště, 686 01, Czechia
  • Local Institution - 0176
    Ratingen, North Rhine-Westphalia 40878, Germany
  • Local Institution - 0101
    Cologne, 50937, Germany
  • Local Institution - 0199
    Erlangen, 91054, Germany
  • Local Institution - 0046
    Hamburg, 20095, Germany
  • Local Institution - 0075
    Magdeburg, 39120, Germany
  • Local Institution - 0201
    Minden, 32429, Germany
  • Local Institution - 0074
    Tübingen, 72076, Germany
  • Local Institution - 0025
    Veszprém, Veszprém City 8200, Hungary
  • Local Institution - 0197
    Budapest, 1062, Hungary
  • Local Institution - 0066
    Debrecen, 4032, Hungary
  • Local Institution - 0028
    Gyula, 5700, Hungary
  • Local Institution - 0024
    Hódmezővásárhely, 6800, Hungary
  • Local Institution - 0027
    Kistarcsa, 2143, Hungary
  • Azienda Ospedaliera Universitaria Careggi-Reumatologia
    Florence, 50141, Italy
  • AOR San Carlo di Potenza-UOC Reumatologia
    Potenza, 85100, Italy
  • Local Institution - 0097
    Roma, 00168, Italy
  • Local Institution - 0202
    Nagoya, Aichi-ken 457-8511, Japan
  • Local Institution - 0106
    Nagoya, Aichi-ken 4678602, Japan
  • Local Institution - 0151
    Sapporo, Hokkaido 0608648, Japan
  • Local Institution - 0179
    Tsu, Mie-ken 514-8507, Japan
  • Local Institution - 0123
    Kawachi-Nagano, Osaka 586-8521, Japan
  • Local Institution - 0205
    Bunkyō, Tokyo 113-8519, Japan

Showing the first 100 of 138 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Nov 2024, 39 months.

Results were first posted in Apr 2025, 5 months after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 39 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2021
First posted
Jun 1, 2021
StartActual
Jul 15, 2021
Primary completionActual
Nov 7, 2024
CompletionEst.
Nov 12, 2026
Results first posted
Apr 13, 2025
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04908189
Responsible party
Sponsor
First posted
Jun 1, 2021
Start date
Jul 15, 2021
Primary completion
Nov 7, 2024
Completion
Nov 12, 2026 (estimated)
Results posted
Apr 13, 2025
Last update
Sep 11, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion